IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.
Proteome Sciences is a CRO specializing in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterize proteins and their associated post-translational modifications. By using LC-MS2, SysQuant®, and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up- or down-regulated with disease progression or drug treatment.
Invivoscribe® is a comprehensive CDx partner, providing ISO 13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. It offers internationally standardized testing through ISO 15189 laboratory network (US, Europe, Asia). Its Streamlined CDx™ model has proven successful in accelerating FDA, EMA and PMDA approvals of new targeted therapies.
Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. KREX was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events (irAEs). Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
Imagia brings together healthcare expertise and advanced artificial intelligence to diagnose, treat, and cure high burden diseases. Through its EVIDENS platform, Imagia enables its stakeholders to learn from distributed healthcare data and discover AI-driven clinical solutions. Working collaboratively with hospital, biotech, pharma, and medical device partners, Imagia is on a mission to unleash the potential of all data across all organizations to achieve medical breakthroughs.
Paragon Genomics, Inc. specializes in sample preparation for targeted next-generation sequencing (NGS). We develop and commercialize reagents and molecular diagnostic tools for genomic analysis of clinically-relevant samples. Our CleanPlex® and CleanPlex® UMI NGS panels combine superior primer design and innovative library preparation chemistry to eliminate non-specific PCR products, incorporate molecular identifiers, and achieve superior target enrichment and variant detection performance.
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments.
Flagship Biosciences, Inc. is a technology driven tissue analysis services company delivering the most accurate and informative data for improved drug development. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. www.flagshipbio.com
Eutropics, a clinical diagnostics company, is developing novel, functional assays that enable personalized medicine approaches to treating cancer.
Eutropics’ PraediCare DxTM platform delivers medically useful insight that accelerates drug development and guides treatment.
Based on the principles of apoptosis biology, the Praedicare DxTM platform provides predictive functional biomarkers for liquid ad solid cancers.
The Mcl-1 Dependency Assay is a Laboratory Developed Test (LDT) for Alvocidib, and becoming a companion diagnostic for other MCL1 targeting therapies.
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine
We develop innovative immunohistochemistry (IHC) and in situ hybridization (ISH) instruments and tissue-based reagents that empower researchers. Our instrument and protocol flexibility allow for multiplex IHC, gene and protein ISH/IHC, mRNA ISH, miRNA ISH, DNA ISH, and the most challenging assays. Accelerate the discovery of new targets and biomarkers, speed assay development and target validation using DISCOVERY products.